Yahoo
NasdaqGS - Delayed Quote USD

Inhibrx Biosciences, Inc. (INBX)

108.65 -18.93 (-14.84%)
At close: May 12 at 4:00:01 PM EDT
108.00 -0.65 (-0.60%)
Pre-Market: 8:13:06 AM EDT
Trade INBX on Coinbase
Chart Range Bar
Loading chart for INBX
  • Previous Close 127.58
  • Open 125.00
  • Bid 106.11 x 500
  • Ask 114.10 x 500
  • Day's Range 99.20 - 125.00
  • 52 Week Range 10.84 - 155.29
  • Volume 1,260,587
  • Avg. Volume 370,131
  • Market Cap (intraday) 1.587B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -9.04
  • Earnings Date May 14, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 265.00

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

inhibrx.com

109

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: INBX

Trailing total returns as of 5/12/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INBX
37.53%
S&P 500 (^GSPC)
8.11%

1-Year Return

INBX
827.84%
S&P 500 (^GSPC)
26.64%

3-Year Return

INBX
830.21%
S&P 500 (^GSPC)
79.46%

5-Year Return

INBX
830.21%
S&P 500 (^GSPC)
82.15%

Earnings Trends: INBX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -32.83M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-30M
-20M
-10M
0

Analyst Insights: INBX

View More

Analyst Price Targets

230.00
265.00 Average
108.65 Current
300.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/8/2026
Analyst Stifel
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 150

Statistics: INBX

View More

Valuation Measures

Annual
As of 5/8/2026
  • Market Cap

    1.96B

  • Enterprise Value

    1.95B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.60k

  • Price/Book (mrq)

    245.53

  • Enterprise Value/Revenue

    1.50k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.58%

  • Return on Equity (ttm)

    -197.85%

  • Revenue (ttm)

    1.3M

  • Net Income Avi to Common (ttm)

    -140.06M

  • Diluted EPS (ttm)

    -9.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    124.22M

  • Total Debt/Equity (mrq)

    1,338.82%

  • Levered Free Cash Flow (ttm)

    -84.46M

Compare To: INBX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: INBX

Fair Value

108.65 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: